Business & Finance · October 29, 2026
Eli Lilly Shares Surge on Raised Sales Forecast
Eli Lilly reported third-quarter 2026 earnings that exceeded analyst estimates, leading the company to raise its full-year revenue outlook for the third time this year. The growth is primarily driven by high demand for its GLP-1 medications, specifically the obesity drug Zepbound and the diabetes treatment Mounjaro. While the injectable medications saw significant sales growth, the company's new obesity pill, Foundayo, performed below expectations. Following the report, the company's stock reached a record high, bringing its market valuation to approximately $1.2 to $1.3 trillion.
Read the original coverage
- CNBCMainstream
Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion
Read at CNBC ↗ - MarketWatchFinancial
Lilly raises outlook for third time this year as Zepbound sales soar.
Read at MarketWatch ↗ Eli Lilly Shares Surge on Raised Sales Forecast
Read at Bloomberg ↗- New York PostTabloid
Big, fat demand for weight-loss drugs fuels Eli Lilly stock surge — as market cap hits $1.2 trillion
Read at New York Post ↗
Reported by multiple outlets
- Eli Lilly reported third-quarter earnings and revenue that exceeded market expectations.
- The company raised its full-year sales outlook for 2026.
- Demand for the drugs Zepbound and Mounjaro surged during the quarter.
- The company's stock price increased following the earnings announcement.
Reported by only some outlets
- Eli Lilly now expects 2026 revenue to be between $91 billion and $92 billion.
- Foundayo sales were lower than Wall Street expectations.
- Over 500,000 patients are using Lilly injections through Medicare.
- Medicare patients pay a reduced price of $50 a month for the injections.
- Recent acquisitions including AtaiBeckley and Curevo reduced forecasted profit shares by 50 cents.
Industry-friendly coverage frames it as…
emphasize the record-breaking market valuation, the expansion of the obesity market, and the significant revenue guidance hikes as indicators of robust growth.
Skeptical / consumer coverage frames it as…
note that while overall sales are high, the new oral pill Foundayo missed expectations and acquisitions have slightly dampened the profit per share outlook.
Numbers that differ
- Market Capitalization: New York Post reports both $1.2 trillion (summary) and $1.3 trillion (body).
FreeDaily Brief newsletter
Get the 5-minute Daily Brief, with the topics you pick.
The Daily Brief is free
About these outlets
CadNews does not determine absolute truth or endorse political viewpoints. It compares publicly available reporting, identifies shared facts, highlights framing differences, and flags uncertainty.